Home » Posts tagged 'New York City'
Tag Archives: New York City
It’s winter, which we sometimes call “flu season.” In fact, “you can catch influenza at any time during the year if exposed to the virus, and its severity is the same regardless of when you get sick,” says Edgardo Sanabria-Valentín. We don’t fully know the answer to why influenza is more common during the colder months. According to Nathan Lents, “The virus is viable for a longer time in cold air, and spreads more readily in dry air. Another reason that may contribute is that winter air dries our mucus membranes, which makes them less effective at preventing viral entry. We also tend to spend more time indoors with closed windows and recirculated air.”
A somber anniversary
The 2018 flu season was also the 100th anniversary of the infamous global influenza pandemic, a year when more
than 500 million people around the world are estimated to have died from flu. Of that number, 675,000 fatalities came from the United States, with roughly 20,000 from New York City alone. According to Mike Wallace, in his 2018 book Greater Gotham, more Gothamites died of disease in the city than died during World War I; the ongoing war effort actually impaired New York’s efforts to fight the flu, by concentrating soldiers in training camps where disease could spread and by taking much-needed medical personnel away from home to establish medical camps near the battlefields in Europe.
Despite the high numbers of fatalities at home, New York of 1918 had a lower death rate than other major cities (4.7 deaths per 1,000 residents, as compared to Boston’s rate of 6.5 and Philadelphia’s of 7.3). This was attributed by Health Commissioner Royal Copeland to New York’s long history of public health work, and particularly the alleviation of unhealthy conditions around the city at the turn of the 20th century.
Vaccines and you
Today, scientific and public health efforts have brought some protection from a repeat of 1918 in the form of vaccines. In the case of the flu, explains Dr. Lents, “Each year’s vaccine is targeted toward the three to four strains that appear to be spreading the most rapidly. The injected vaccine contains killed viruses [from those strains], while the nasal spray contains live but weakened viruses. In both cases, the large dose of viral particles elicits a strong immune reaction from our bodies, including the production of antibodies that can stick around for years or even decades. The second time we are exposed to the same virus, it only takes a day or two to mount the same level of immune response. This ‘priming’ gives the immune system enough of a head start that it usually prevents the infection from ever taking hold.”
Because the influenza virus is so good at mutating from year to year, “no vaccine is 100% perfect, and getting the flu shot will never protect you against 100% of all flu strains,” says Dr. Sanabria-Valentín. But the vaccine will “significantly decrease the risk of getting sick, and will decrease the severity and length of infection, and decrease the chance that you get other people sick” if you do contract the virus.
Vaccinating also helps to protect those around you in other ways, namely by contributing to “herd immunity.” “Some people cannot be vaccinated because they are too young, too old, immune-compromised, or battling other kinds of infections,” says Dr. Lents. When the percentage of people in a population are effectively immunized, it helps to prevent the spread of disease to those who were unable to receive the vaccine. But when the percentage of vaccinated people falls because individuals who otherwise could be immunized choose not to be, it puts vulnerable populations at risk.
Conquering vaccine hesitancy
“Controversies about vaccinations have been out there since we adopted this preventative measure almost 100 years ago,” says Dr. Sanabria-Valentín. “There are a lot of myths about vaccinations which are peddled by conspiracy theorists trying to sell you something or by people who might have good intentions but got swindled by ill-intentioned people trying to make a fast buck. One of the most popular ones is that vaccines can cause autism in children. This claim was first made in a study that was demonstrated (by many groups) to be fraudulent; no direct relationship between receiving vaccinations and autism has been found. There is overwhelming consensus among scientists and physicians that vaccines are safe and effective even though, like most medical treatments, in very rare cases they can cause side effects and in even rarer instances can cause serious unintended health problems. There is overwhelming evidence that vaccination has helped not just individuals, but humankind.” Although diseases like smallpox, polio and the measles were all but eliminated by vaccine technology, skepticism about immunization–which many attribute to the rise of social media–has caused some long-gone diseases to stage a comeback.
Dr. Lents stated that “in 2017, 80,000 people died of influenza, the highest number in 40 years. If more healthy people had been vaccinated, that number could have been much less. Each person that decides not to vaccinate adds a little bit of risk to the entire population.” This dynamic played out in October 2018, when measles–which was declared eliminated in the US in 2000–broke out in Williamsburg, Brooklyn. The New York City Department of Health confirmed 42 cases in Williamsburg and Bensonhurst as of mid-December, and is currently barring un-immunized students from attending local schools. And according to The Guardian, Europe is also experiencing a surge in vaccine hesitancy and a corresponding growth in the numbers of new measles cases; Europe will see more than 60,000 new cases this year and 72 deaths, the highest number this century.
It is generally agreed that fears about vaccine side-effects are overblown, and contradicted by scientific consensus. “Vaccines are constantly monitored and modified as circumstances dictate. The FDA does not approve a vaccine unless initial trials indicate the benefits clearly outweigh the risks. In response to vaccine safety concerns today, healthcare providers have to give vaccine information sheets to recipients clearly describing the risks and benefits of the vaccine. And finally, vaccines are subject to particularly high safety standards because, unlike other health treatments, they are given as preventive measures to protect healthy people,” explains Dr. Evelyn Aranda Jaque. “Although vaccination is not 100% effective, studies on flu vaccination programs have shown that people who get vaccinated are less likely to be seriously ill or die in comparison with those who do not vaccinate. We must consider that the widespread use of vaccines for life-threatening diseases in the United States has led to a dramatic decrease in their incidence.”
Evelyn Aranda Jaque is a substitute Associate Professor at John Jay College, where she teaches classes including Immunology and Microbiology. She received her Ph.D. from the Physiology Department at Pontificia Universidad Católica de Chile. Dr. Aranda Jaque’s research since her doctorate days has largely focused on the role of angiogenesis (the formation of new blood vessels) in tumor progression.
Nathan Lents is a Professor of Biology and Director of the Honors Program and Macaulay Honors College at John Jay College. He holds a Ph.D. in human physiology and postdoctoral training in computational biology from NYU. In addition to his laboratory research, Dr. Lents writes popular science articles, blog and books. His most recent book is Human Errors: A Panorama of Our Glitches from Pointless Bones to Broken Genes.
Edgardo Sanabria-Valentín is the Associate Program Director of John Jay College’s Program for Research Initiatives in Science and Math (PRISM) as well as the college’s Pre-Health Careers Advisor. He holds a Ph.D. from NYU-School of Medicine, and spent three years working in the biotechnology industry. Dr. Sanabria-Valentín is the recipient of the ESCMID Young Scientist Award (2007), a Leadership-Alliance Schering Plough Graduate Fellowship (2006), and the NBHS-Frank G. Brooks Award for Excellence in Student Research (2001).
Mike Wallace is a Distinguished Professor of History at John Jay College and author of Greater Gotham: A History of New York City from 1898 to 1919. Dr. Wallace is also the co-author of Pulitzer Prize-winning Gotham: A History of New York City to 1898 and the founder of the Gotham Center for New York City History at the CUNY Graduate School. He received his undergraduate and graduate degrees from Columbia University.
The terms “opioid crisis” or “opioid epidemic” have come to be used as political buzzwords, but what does it really mean to say that America is in the grip of an “opioid epidemic”? According to the Centers for Disease Control, more than 72,000 people in the United States died as the result of an overdose in 2017, and approximately 30,000 of these were from the use of fentanyl and other synthetic opioids — that comes to around 100 per day! Fentanyl, a powerful opioid designed to treat severe and chronic pain, is roughly 100 times stronger than morphine, and is currently being used to adulterate other abused substances, making these overdoses likely to increase.
From the perspectives of policy, policing, and public health, this rash of deaths is worthy of further consideration. John Jay College scholars from across disciplines and research areas tell us what they think has contributed to the trend of deaths from opioid abuse and what approaches may be best suited to tackling the problem.
What is different about the pattern of drug abuse we are seeing today that has caused it to be referred to as the “opioid epidemic”?
Jeff Coots (Director, From Punishment to Public Health Initiative): One main reason for concern around opioids today is that they are simply more deadly than the other drugs we consume. However, the rates of overall illicit drug use are actually quite steady — especially when we remove cannabis consumption from the conversation. The latest results from the National Survey on Drug Use and Health show steady illicit drug consumption from 2002-2013 at about 4%, with those aged 18-25 using a bit more than twice the rate of other age groups. We do see a slight increase in heroin consumption as prescription opioids become less available, but this doesn’t impact the overall rates of illicit consumption.
Heidi Hoefinger (Visiting Scholar, Anthropology): The situation is considered an “opioid epidemic” due to the size of the problem now, and its potential for growth. But this issue is also getting more attention than past drug “epidemics” because it’s a white, middle-class problem, particularly here in New York, with Staten Island and Long Island having some of the highest rates of use and overdose. There has definitely been a “softer” approach to this epidemic as opposed to the “crack epidemic” of the 1980s, which saw much more aggressive law and order efforts resulting in mass incarceration. Many poor people of color are still sitting in prison because of that heavy-handed approach. It’s definitely a good thing that opioid addiction is currently being viewed as more of a public health issue, but it’s extremely problematic that Black and Latinx folks continue to suffer the consequences of racist applications of drug policy.
Can you point to a few of the key factors that you believe are to blame for the current public health crisis?
Jeff: The origins of the current crisis began with the marketing of OxyContin as a non-addictive painkiller in the 1990s followed by the introduction of “pain” as the fifth vital sign in 2001. This led to higher rates of opioid prescription drug use and related overdose fatalities in the early 2000s. The second “wave” of opioid-related deaths are attributed to increased heroin consumption starting in about 2010, following a crackdown on prescription opioid distribution — consumers simply switched to the cheaper and more available opioid. The third wave is attributed to the increased presence of synthetic opioids like fentanyl in the market, starting in about 2013. These synthetics can be much more potent and make it difficult for users to control their dosage, leading to more overdoses.
Marta Concheiro-Guisan (Assistant Professor, Forensic Toxicology): Other socioeconomic factors like unemployment and economically-depressed areas should also be considered in trying to understand the whole problem and the populations most affected by it.
Heidi: The biggest drivers are probably Big Pharma and corporate greed because pharmaceutical companies were deceptive about the true effects of opioids, claiming they were non-habit inducing. They also offered incentives to doctors for prescribing, which led doctors to over-prescribe opioids instead of safer alternatives. Insurance companies typically cover opioids as opposed to alternative therapies, so they’ve played a role in this as well. It’s encouraging to see that NYC (among other cities) is suing some major pharmaceutical companies for their role in the epidemic, but there still needs to be more accountability on the part of Big Pharma.
What are the implications for American society should this systemic issue continue unabated?
Jeff: I think we are having a really important debate in the country right now about how our collective response to drug use differs along racial lines. Drug Policy Alliance and Columbia University co-hosted a conference in 2016 to highlight how the white opioid user who may have started on prescription drugs and then switched to heroin is considered a victim of circumstance and provided overdose treatment, rehabilitation and a call for compassionate public health responses. Meanwhile, black and brown heroin addicts who may not have had health insurance and access to prescription drugs tend to get jail cells, court-mandated treatment and moralizing “just say no” campaigns grounded in personal responsibility. Obviously, the the shift towards funding treatment and reducing criminal justice involvement is welcome, but the carnage reaped in the previous regime of zero tolerance and deterrence must be acknowledged and reconciled at the local and national levels.
Heidi: It has been compared to HIV in some arenas, in that it’s affecting a marginalized and stigmatized population (e.g., drug users) but it’s not getting the same attention and funding it deserves. The numbers of overdoses and deaths will likely continue to rise as long as the stigma exists, and as long as pharmaceutical companies continue to operate unchecked, as long as doctors continue over-prescribing, as long as insurance companies don’t see the value in covering alternative treatments, and as long as harm reduction remains undervalued and underfunded.
Marta: The biggest impact on American society is, of course, the tragedy of the families affected by this unprecedented health issue, and the loss of so many young people’s lives. The Centers for Disease Control and Prevention estimates that the total “economic burden” of current opioid misuse alone in the United States is $78.5 billion per year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement.
The Opioid Crisis Response Act of 2018 was recently signed into law. It authorizes new funding and grants to address the crisis, advances initiatives to raise awareness and to get more first responders to carry naloxone, and drives increased coordination among federal agencies to stop drugs like fentanyl at the border, among other measures. Do you think this bill takes the right approach to dealing with the crisis? Does it go far enough?
Heidi: Many of these are welcome changes, and are actually similar to Obama’s opioid plan from 2016, but the problem is that this plan doesn’t allocate much more funding — which is needed. If this is a serious public health problem, it should receive funding and attention similar to that provided for HIV/AIDS or Ebola, as well as a similarly concerted, multi-organizational response. But addiction is still a very stigmatized condition, and not taken as seriously as it should be. People with addictions are still often blamed for their own demise, and not viewed in the same light as people with other chronic illnesses.
Marta: From my point of view, one critical element in addressing this crisis is the treatment of addiction as a health issue rather than as a stigma, and a drastic improvement of current services and their accessibility. Another important aspect is education for the general population and among professionals such as medical doctors. More funds are also necessary for the forensic sciences to develop a clearer picture of the current crisis, to know all the opioids that are involved, to monitor future crises, and to research addiction.
Jeff: We need to invest heavily in reducing demand and mitigating the risks associated with consumption, rather than focus on interrupting supply. Efforts to control access to drugs have failed for over a century. In reducing demand, we need to do a better job of addressing pain and trauma, take a hard look at our overreliance on pharmaceuticals and reduce the number of people who become addicted in the first place. In working with those already experiencing opioid dependence, we need to provide competent and evidence-based care including Medication Assisted Treatment (MAT), which is the gold standard for treating those with opioid disorders. In terms of mitigating risks, increased naloxone access is crucial, but increased use of other Harm Reduction strategies is needed as well.
What do you believe is the best way to address this epidemic?
Marta: This epidemic has to be addressed with a multidisciplinary approach, as indicated by the National Institute on Drug Abuse (NIDA) and other governmental agencies. Promoting the use of naloxone, the improvement in the accessibility of medical assistance and addiction treatments, the expansion of prevention programs in schools and for the general public, and increasing funds for the forensic sciences and addiction research are among what I consider the priority areas.
Jeff: The best way to reduce the impact of opioid overdose fatalities is to focus on saving the lives of those who choose to consume opioids. This strategy, more commonly known as Harm Reduction, focuses on reducing the negative side effects associated with illicit drug use, rather than punishing and/or moralizing at those who engage in use. These strategies include needle exchange programs, peer-based education, MAT programs, and safe consumption facilities, all of which treat those who consume illicit drugs as human beings worthy of compassion and competent medical care for their medical issues. As I noted earlier, our previous strategy of interrupting supply and punishing consumption — i.e., the War on Drugs — has not reduced the rates at which our citizens consume illicit drugs. It has, however, made that consumption more dangerous and more damaging for those communities with higher rates of use and criminal justice presence.
Heidi: Societal attitudes towards drug users and people with addictions need to change. For this to happen, people need to understand that drug use has always been a part of human history, drug users are not inherently bad people, and people will continue to want to alter their consciousness or treat pain through drug use. People also need to understand the racialized history of drug policy in this country, and that laws against drug use (which are unevenly applied across race and class) were implemented for racial, class and economic reasons (and because of who was using the drugs), not necessarily because of the harmful effects of the drugs. When people are exposed to this history, and these realities, then perhaps stigma against drug use will change, and people affected by the current epidemic will get the proper help that they need.
In addition, we need more funding for harm reduction and evidence-based drug education programs in middle schools, high schools, college and universities. Not the “Just Say No” type, because those don’t work. But the kind where students can ask open, honest questions and get factual, evidence-based, non-biased, non-moralistic responses so they can know the potential effects and risks and make more informed decisions. And there also needs to be more support for medication-assisted treatment programs (like methadone and buprenorphine), as well as harm reduction programs like DanceSafeNYC that provides factual, evidence-based drug education and drug checking kits at music festivals and events. These types of initiatives take harm reduction beyond syringe exchange programs and make them more accessible to a diverse range of young people, which ultimately saves lives, and may start to turn the tide of this epidemic.
Marta Concheiro-Guisan, Ph.D., is Assistant Professor of Forensic Toxicology at John Jay College. She has experience in the development and validation of new analytical methods and toxicological analysis of different types of specimens–including plasma, blood, urine, oral fluid, hair, sweat and other tissues. She has participated in Drugs and Driving Research Projects, including the ROSITA (Road Site Testing Assessment) and DRUID (Driving Under the Influence of Drugs) European Projects, to study alternative matrices to detect drug impairment, and in clinical protocols involving different types of drugs of abuse and drug exposure during pregnancy. Dr. Concheiro-Guisan has more than 40 publications in peer-reviewed journals.
Jeff Coots, JD, MPH, serves as the Director of the From Punishment to Public Health (P2PH) initiative based at John Jay College. Prior to joining P2PH, Mr. Coots completed a joint Juris Doctor/Masters of Public Health degree program at Northeastern University School of Law and Tufts University School of Medicine, where he focused his studies on the social justice and health impacts of mass incarceration. While in Boston, he served as an Albert Schweitzer Fellow and delivered dialogue-based “Health Reentry” workshops to introduce strategies for working in collaboration with a primary care provider to prevent new infections and mitigate the effects of chronic disease.
Heidi Hoefinger, Ph.D., is a Visiting Scholar in John Jay College’s anthropology department, where she teaches a course on gender and sexuality within the social and cultural contexts that exist in an increasingly integrated but unequal global world. She also works on a large European Research Council (ERC) project led by Kingston University in London, in which she is the New York-based ethnographer looking at anti-trafficking efforts in New York City, and their effect on sex work/ers and migration policy. Among her areas of interdisciplinary research interest are gender and sexuality, globalism and transnationalism, and drug use.
By Raymond Legendre
Amidst the deadliest drug epidemic in American history, the National Network for Safe Communities (NNSC) hosted a documentary film screening and panel discussion on October 2 that highlighted why the opioid crisis is so difficult to stop, and shared the actions being taken in New York City to save lives.
The event featured the Mother Jones short documentary series, Finding a Fix, with a brief introduction by filmmaker Mark Helenowski, and a subsequent panel conversation including New York City council member Stephen Levin, Manhattan Assistant District Attorney Kaitrin Roberts, and community organizer Marilyn Reyes, co-chair of the Peer Network of New York. Mother Jones reporter Julia Lurie also participated on the panel, which was moderated by NNSC Director David Kennedy.
In 2017, drug overdoses claimed an estimated 72,000 lives in the U.S., according to the Centers for Disease Control and Prevention. Of those deaths, more than 49,000 were attributed to opioids. New York City alone recorded around 1,500 overdose deaths last year. The current death rate is equal to one New Yorker dying from an overdose every six hours, according to ADA Roberts. The availability of Narcan, a nasal spray that can reverse opioid overdose, is often the different between fatal and non-fatal overdoses, the prosecutor also noted. In August 2017, New York became the first state to make no-cost or lower-cost medicine to reverse opioid overdoses available at pharmacies.
Dr. Edgardo Sanabria-Valentín sees himself in the PRISM students he works with. He credits his alma mater, the University of Puerto Rico, with instilling in him the spirit of preparedness that he brings to student researchers and presenters at John Jay — being ready not only with the technical facts but with the message about why your research is important, and how you are changing the world.
“Because of that, every time we go to a conference, we get minimum one award — my top is three!” he says. “Every time we go to an undergraduate research conference, John Jay’s name always comes up.” It is this tangible commitment to bringing out the best in John Jay’s science students that earned Dr. Sanabria-Valentín, who is the Associate Director of the John Jay Program for Research Initiatives in Science and Math (PRISM), a 2018 APACS President’s Award.
At its heart, PRISM is about teaching students skills, not only in the sciences but also to prepare them to succeed in and after college. “The bread and butter upon which PRISM was founded” is the Undergraduate Research Program. The program provides students with opportunities to be exposed to the process of science beyond their normal classroom studies by working directly with a faculty mentor on an original STEM research project.
And PRISM has grown. A second component is the Junior Scholars program, giving academic support to eligible students that can include stipends, professional development events and supplementary advisement, as well as financial support in applying to post-graduate programs in New York State-licensed professions. Just as important for an institution that counts many first-generation college students among its student body, Junior Scholars collaborates with student support services across the college, like the Math and Sciences Research Center, Center for Career and Professional Development, Wellness Center, Center for Postgraduate Opportunities, and even more. The program is designed to make sure that students have all the tools to get to know their college and excel.
External funding is part of what drives PRISM’s growth. The New York State Collegiate Science and Technology Entry Program, or CSTEP, awards grants to postsecondary and professional schools to start academic support programs — like PRISM — for students from underrepresented minority groups, or who are economically disadvantaged, to help them get into STEM fields. John Jay was among the first class of schools to receive CSTEP funding, thirty years ago and out of roughly 200 PRISM students, the CSTEP grant supports 140. Edgardo’s goal is to double that number over the next five years.
His hard work is a large part of why the CSTEP program is at John Jay — after a short hiatus, Edgardo’s application brought the program back in 2015 — and of John Jay’s unique status as the only school to have institutionalized this type of academic STEM-focused support initiative. He is also responsible for collaborating with other CSTEP schools in the region: NYU, Hostos Community College, Fordham, City College and Mt. Sinai are among the Manhattan and Bronx institutions that participate with John Jay in our CSTEP Regional Research Expos. Participating students are invited to present their own research in poster sessions and attend professional development activities.
His work on and logistical support for the expos has earned Edgardo an award from the President of the Association of Program Administrators for CSTEP and STEP (APACS). The honor also recognizes his success in running a program that benefits students in the sciences. The advisement services offered by PRISM have created the conditions for increased student success at John Jay and degree completion, and the program puts students on a path toward the pursuit of higher degrees, or toward a place in the workforce in a variety of science, technology and computer science fields. The Undergraduate Research Program has measurably helped students to pursue post-graduate degrees in science, medicine and more.
The bottom line for Edgardo, though, is his students. “My kids blow me away every time,” he gushes. “I have complete pride in showing them off at every conference I go to. I have learned so much by helping them with posters and advising on their projects; it’s encouraging that I sometimes find my students to be smarter than me.”
Learn more about:
CSTEP in New York State: http://www.highered.nysed.gov/kiap/colldev/CollegiateScienceandTechnologyEntryProgram.htm
Edgardo Sanabria-Valentín, Ph.D. is the Associate Program Director for PRISM and also the Pre-Health Careers Advisor at John Jay. He holds a Ph.D. from NYU-School of Medicine, where his dissertation work involved studying the mechanisms Helicobacter pylori employs to persist in the human stomach for the life span of each host. He came to John Jay after a Post-Doctoral Fellowship at Harvard Medical School followed by 3 years working in the Biotechnology Industry in Boston. Dr. Sanabria-Valentín is the recipient of the ESCMID Young Scientist Award (2007), a Leadership Alliance-Schering Plough Graduate Fellowship (2006), and the NBHS-Frank G. Brooks Award for Excellence in Student Research (2001). He is also a founding member of the NYC-Minority Graduate Student Network and The Leadership Alliance Alumni Association.